Western immunoblotting showed that MGCD516 treatment not only resulted in significant blockade of phosphorylation of multiple RTKs such as PDGFR, c-Kit and IGF1-R but also inhibited downstream effectors such as p-AKT and p-S6 which are critical for tumor cell survival and proliferation. This evidence concerns the gene AKT1 and neoplasm.